Sartorius Stedim Biotech (SSB) has revised its full year guidance after its range of single-use products drove revenue gains in the first half of 2011.
ShangPharma said it saw revenue climb on higher customer spending in the fourth quarter, but that margins slid due to currency effects and higher share-based compensation.
Wuxi PharmaTech finished the fourth quarter and the full year 2010 on a high driven by growth across all business units and the payoff from former suitor Charles River Laboratories (CRL).
Nearly half of healthcare supply chain executives are planning to expand into emerging markets in the next 18 months, according to a UPS survey, but are concerned about the process.
Patheon has posted a 12 per cent growth in operating profit in the second quarter and said there is “strong evidence” the business environment is improving.
Kendle International posted a 22 per cent drop in net income to $5m, after a computer error led to problems with a clinical trial carried out for one of its customers.
Pfizer is likely to lose its crown as the world’s largest pharmaceutical company and by 2012 will be usurped by GlaxoSmithKline, according to a report from Urch Publishing.
Gerresheimer’s decision to concentrate on the pharmaceutical and life science sectors and sell-off non-core divisions appears to be paying dividends judging by a 14 per cent jump in third quarter operating profit.
Agilent recorded strong third quarter revenue growth for its Bio-Analytical segment, which was tempered by the stagnation of income from its Electronic Measurement division.
Invitrogen’s plans to buy Applied Biosystems (ABI) are on track with US antitrust regulators approving the deal and both firms achieving strong revenue growth.
Affymetrix slumped to an operating loss in the second quarter of 2008, reporting flat revenues and blaming a 30 per cent reduction in sales to the pharmaceutical sector.
With fears of a global recession riding on the back of the credit crisis, many laboratory suppliers have managed to weather the storm and still achieve double digit sales growth in the second quarter of 2008.
Although Japan's pharma market sits in firm second position on the
global stage, the country's foothold is slipping as other more
innovative countries grasp for a greater presence.
Quintiles Transnational has heralded the results of an
independently conducted study of clinical investigator sites across
Europe that saw the firm rate the highest overall in terms of
satisfaction.
With active pharmaceutical ingredient sales of $1,460m (€960.8m) in
2007 and a portfolio of more than 250 compounds, Teva
Pharmaceutical Industries is by a long stretch the dominant
supplier in the global API market.
Jubilant Organosys, India's largest custom research and
manufacturing services (CRAMS) provider, has scored new contracts
to the tune of $92m for the year thus far as its business continues
to gather momentum.
Beckman Coulter saw its fourth quarter earnings held back by
the cost of acquiring NexGen Diagnostics, but the
underlying business was strong with a near-11 per cent hike in
revenues.
Another sharp decline in biomedical production saw overall
manufacturing output in Singapore fall for the second month running
in December, prompting fears that the heavily trade-reliant economy
could buckle under a looming US recession.
New research from Frost & Sullivan provides a snapshot of
biopharma spending trends on contract research organisations
(CROs), along with forecasts for industry growth.
Applied Biosystems (ABI) saw 5 per cent revenue growth during its
first quarter of fiscal 2008 as sister company Celera posted
revenue growth of 57 per cent.
Sigma-Aldrich continued its strong year with both revenues and
pre-tax profits showing strong double-digit growth in the third
quarter predicting it will break the $2bn (€1.4bn) revenue mark
this year.
Scanning probe microscope maker Veeco has seen its third quarter
revenues drop 13 per cent to $97.7m (€68.7m) and plans to make 100
staff redundant as part of a restructuring drive.
PRA said it signed an agreement with equity firm Genstar Capital to
be bought back by the firm for around $790m (€580m) while the CRO
posted a 90 per cent tumble in profit in Q2 due to heavy
restructuring charges.
PPD has posted positive financial results for the second quarter of
the year in net contrast to its lacklustre performance in Q1, but
cut its earning outlook for the full year.
LabTechnologist.com brings you an exclusive interview with Chris
van Ingen - the president of Agilent's Life Science and Chemical
Analysis (LSCA) division.
Charles River has posted first quarter results that beat analysts
expectations after seeing renewed growth in its research models and
services segment.
One-off costs related to last year's acquisition of Serologicals
and a continuing manufacturing consolidation strategy were largely
responsible for sharp falls in Millipore's pre-tax and net profits
for the first quarter...
Biotech giant Amgen has posted healthy results for the first
quarter following a positive performance by its blockbuster anaemia
drug Aranesp (darbepoetin alfa).
An increasing number of factors are luring sponsors to offshore
clinical trials to 'hidden gems' across the globe, delegates heard
at this week's Accelerating Patient Recruitment & Retention in
Clinical Trials conference,...
Genentech, the world's second biggest biotech company, has shown a
strong performance in the first quarter while its main rival Amgen
is trying to regain momentum after a difficult year.
Parexel has announced encouraging financial results for its second
fiscal quarter, despite 'disappointing' performance in its medical
communications business.
More companies in the pharmaceutical industry than any other
industry are set to increase their reliance on information
technology (IT) and business process (BP) outsourcing this year,
new research indicates.
A new report out this week suggests the pharma industry is losing
the trust of its key stakeholders. The report, compiled by
PricewaterhouseCoopers (PwC), concludes that the growing decline in
the pharmaceutical industry's reputation...
Although US spending on healthcare rose by 6.9 per cent in 2005,
taking it to almost $2 trillion (€1.5 trillion), it's the smallest
increase since 1999, down from 7.2 per cent in 2004 and 8.1 per
cent in 2003.
The contract research organisation (CRO) industry is in full swing
as the clinical trial outsourcing trend continues, but where is the
money being spent?
Massachusetts-based Millipore has reported a fall in net profit in
its third quarter results, mainly due to increased costs and recent
acquisition charges.
